Compare AGX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGX | AXSM |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.0B |
| IPO Year | 1995 | 2015 |
| Metric | AGX | AXSM |
|---|---|---|
| Price | $635.90 | $233.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $409.50 | $211.12 |
| AVG Volume (30 Days) | 307.7K | ★ 873.8K |
| Earning Date | 03-26-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 58.37 | 38.56 |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $944,606,000.00 | N/A |
| Revenue This Year | $33.81 | $57.24 |
| Revenue Next Year | $20.97 | $55.88 |
| P/E Ratio | $211.94 | ★ N/A |
| Revenue Growth | ★ 8.06 | N/A |
| 52 Week Low | $196.90 | $96.09 |
| 52 Week High | $805.75 | $260.19 |
| Indicator | AGX | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 44.41 |
| Support Level | $591.58 | $217.15 |
| Resistance Level | $768.89 | $236.26 |
| Average True Range (ATR) | 44.75 | 9.92 |
| MACD | -13.97 | -1.50 |
| Stochastic Oscillator | 1.86 | 17.27 |
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.